US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neumora Therapeutics, Inc.

0.7569

-0.0425-5.32%

Post-market: 0.76020.0033+0.44%19:46 EDT

Volume:10.85M

Turnover:8.24M

Market Cap:122.43M

PE:-0.47

High:0.8174

Open:0.7911

Low:0.7569

Close:0.7994

Loading ...

Overview Company News Filings

Strategic Adjustments and Future Prospects Drive Buy Rating for Neumora Therapeutics

Stifel Adjusts Price Target on Neumora Therapeutics to $6 From $26, Maintains Buy Rating

MT Newswires Live

Neumora Therapeutics Q4 2024 GAAP EPS $(0.37) Beats $(0.45) Estimate, Cash Balance Of $307.6M

Neumora Therapeutics Inc: to Prioritize Resources Allocated to Navacaprant on Koastal Program

THOMSON REUTERS

Neumora Therapeutics Inc Q4 Shr View $-0.45 -- Lseg Ibes Data

THOMSON REUTERS

Neumora Therapeutics Inc - Discontinues Phase 2 Trial for Navacaprant in Bipolar Depression

THOMSON REUTERS

Press Release: Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Mizuho Securities

Neumora Therapeutics Inc : Mizuho Cuts Target Price to $4 From $20

THOMSON REUTERS

Mizuho Securities Adjusts Neumora Therapeutics Price Target to $4 From $20, Maintains Outperform Rating

MT Newswires Live

Analysts Have Conflicting Sentiments on These Healthcare Companies: Select Medical (SEM), DENTSPLY SIRONA (XRAY) and Neumora Therapeutics, Inc. (NMRA)

3 US Penny Stocks With Market Caps Below $400M

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Neumora Therapeutics, Inc. (NMRA)

Positive Prospects for Neumora Therapeutics: Buy Rating Supported by Leadership Change and Strategic R&D Focus

Neumora Therapeutics Announces Leadership Changes and Strategy

Neumora Therapeutics Names Paul Berns as CEO, Michael Milligan as CFO

MT Newswires Live

Neumora Therapeutics Announces Leadership Transition

THOMSON REUTERS

Neumora Therapeutics Inc - Paul L. Berns to Serve as CEO and Chairman of Neumora

THOMSON REUTERS

Neumora Therapeutics Inc - BILL Aurora to Serve as COO and Cdo, Michael Milligan as CFO

THOMSON REUTERS

Neumora Therapeutics Announces Leadership Transition

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NMRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":0.7569,"timestamp":1751054400000,"preClose":0.7994,"halted":0,"volume":10854038,"hourTrading":{"tag":"盘后","latestPrice":0.7602,"preClose":0.7569,"latestTime":"19:46 EDT","volume":3355195,"amount":2540536.976486,"timestamp":1751067986090},"delay":0,"floatShares":85865485,"shares":161747922,"eps":-1.610306,"marketStatus":"Market Closed","change":-0.0425,"latestTime":"06-27 16:00:00 EDT","open":0.7911,"high":0.8174,"low":0.7569,"amount":8242902.701012201,"amplitude":0.075682,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.610306,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":0.7994,"preHourTrading":{"tag":"盘前","latestPrice":0.8001,"preClose":0.7994,"latestTime":"09:21 EDT","volume":106,"amount":87.9336038,"timestamp":1751030514999},"postHourTrading":{"tag":"盘后","latestPrice":0.7602,"preClose":0.7569,"latestTime":"19:46 EDT","volume":3355195,"amount":2540536.976486,"timestamp":1751067986090},"volumeRatio":16.693809193630077,"impliedVol":3.0628,"impliedVolPercentile":0.824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","floatShares":85865485,"roa":"-48.50%","roe":"-79.05%","lyrEps":-1.529624,"volumeRatio":16.693809193630077,"shares":161747922,"dividePrice":0,"high":0.8174,"amplitude":0.075682,"preClose":0.7994,"low":0.7569,"week52Low":0.611,"pbRate":"0.54","week52High":17.1874,"institutionHeld":0,"latestPrice":0.7569,"eps":-1.610306,"divideRate":0,"volume":10854038,"delay":0,"ttmEps":-1.610306,"open":0.7911,"prevYearClose":10.6,"prevWeekClose":0.7857,"prevMonthClose":0.7163,"prevQuarterClose":1,"fiveDayClose":0.7857,"twentyDayClose":0.7187,"sixtyDayClose":0.9133},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NMRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516573646","title":"Strategic Adjustments and Future Prospects Drive Buy Rating for Neumora Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2516573646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516573646?lang=en_us&edition=fundamental","pubTime":"2025-03-04 02:55","pubTimestamp":1741028124,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on NMRA stock, giving a Buy rating today. Myles Minter has given his Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-adjustments-and-future-prospects-drive-buy-rating-for-neumora-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-adjustments-and-future-prospects-drive-buy-rating-for-neumora-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2516631030","title":"Stifel Adjusts Price Target on Neumora Therapeutics to $6 From $26, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631030","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631030?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:31","pubTimestamp":1741012283,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) has an average rating of buy and mean price target of $12.99, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SF","LENZ","NMRA"],"gpt_icon":0},{"id":"2516680686","title":"Neumora Therapeutics Q4 2024 GAAP EPS $(0.37) Beats $(0.45) Estimate, Cash Balance Of $307.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680686","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680686?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:11","pubTimestamp":1741003885,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Q4 2024 GAAP EPS $(0.37) Beats $(0.45) Estimate, Cash Balance Of $307.6M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44073567/neumora-therapeutics-q4-2024-gaap-eps-0-37-beats-0-45-estimate-cash-balance-of-307-6m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2516874846","title":"Neumora Therapeutics Inc: to Prioritize Resources Allocated to Navacaprant on Koastal Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2516874846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516874846?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:02","pubTimestamp":1741003373,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PL02Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2516687206","title":"Neumora Therapeutics Inc  Q4 Shr View $-0.45 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687206?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:02","pubTimestamp":1741003373,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PL02Q:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2516191687","title":"Neumora Therapeutics Inc - Discontinues Phase 2 Trial for Navacaprant in Bipolar Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2516191687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516191687?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:02","pubTimestamp":1741003373,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PL02Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2516687935","title":"Press Release: Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687935","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687935?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update. KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026. Expect to progress next M4 positive allosteric modulator  program into the clinic by mid-2025. \"The first two months of 2025 have been productive for Neumora. We have analyzed the data set provided by KOASTAL-1 and made important amendments to help optimize the ongoing KOASTAL-2 and -3 studies based on the learnings. We believe these changes strengthen the studies and look forward to delivering topline data in 2026. We've also progressed enrollment in the Phase 1b signal-seeking study for NMRA-511 in Alzheimer's disease agitation and expect to advance our next M4 program into the clinic by mid-2025,\" said Paul L. Berns, chief executive officer, Neumora. \"With our industry-leading pipeline, strong financial","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","LENZ","IE00B19Z4B17.USD","BK4007","IE00B66KJ199.SGD","BK4081","NMRA","BK4139","BK4145","IE0031619046.USD","CTS","PAM","BK4563"],"gpt_icon":0},{"id":"2514809952","title":"Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2514809952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514809952?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:58","pubTimestamp":1740488300,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) today and set a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-inc-nmra-gets-a-buy-from-mizuho-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-inc-nmra-gets-a-buy-from-mizuho-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","MFG","BK4007","NMRA"],"gpt_icon":0},{"id":"2514095663","title":"Neumora Therapeutics Inc : Mizuho Cuts Target Price to $4 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2514095663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514095663?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:32","pubTimestamp":1740486721,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2513142729","title":"Mizuho Securities Adjusts Neumora Therapeutics Price Target to $4 From $20, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2513142729","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513142729?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:32","pubTimestamp":1740403960,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) has an average rating of Buy and mean price target of $12.99, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","MFG","NMRA"],"gpt_icon":0},{"id":"2513742002","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Select Medical (SEM), DENTSPLY SIRONA (XRAY) and Neumora Therapeutics, Inc. (NMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513742002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513742002?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:32","pubTimestamp":1740396762,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Select Medical (SEM – Research Report), DENTSPLY S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-select-medical-sem-dentsply-sirona-xray-and-neumora-therapeutics-inc-nmra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-select-medical-sem-dentsply-sirona-xray-and-neumora-therapeutics-inc-nmra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","BK4185","XRAY","SEM","BK4585","HCSG","BK4007","BK4137","BK4588","NMRA"],"gpt_icon":0},{"id":"2512609541","title":"3 US Penny Stocks With Market Caps Below $400M","url":"https://stock-news.laohu8.com/highlight/detail?id=2512609541","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512609541?lang=en_us&edition=fundamental","pubTime":"2025-02-19 01:11","pubTimestamp":1739898677,"startTime":"0","endTime":"0","summary":"As major U.S. stock indexes hover near record highs, investors are closely watching market movements and economic indicators for signs of future trends. For those interested in exploring smaller or newer companies, penny stocks—though an outdated term—remain a viable investment area with potential value. These stocks, often characterized by lower price points and the possibility of growth, can be particularly appealing when backed by strong financials and solid fundamentals. In this article, we explore three U.S. penny stocks that exhibit financial strength and may offer promising opportunities for long-term success.Overview: Adverum Biotechnologies, Inc. is a clinical-stage company focused on developing gene therapy product candidates for ocular diseases, with a market cap of $92.78 million.Operations: Adverum Biotechnologies generates revenue from the development and commercialization of gene therapeutics, totaling $1 million.Unlock comprehensive insights into our analysis of Adverum","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-us-penny-stocks-market-171117991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4209","SB","BABB","PVL","BK4213","NMRA","BK4139","NRDY","BK4021","ADVM","PHX","BK4204","BK4563","BK4007"],"gpt_icon":0},{"id":"2512158012","title":"Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Neumora Therapeutics, Inc. (NMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512158012","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512158012?lang=en_us&edition=fundamental","pubTime":"2025-02-18 18:51","pubTimestamp":1739875887,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and Neumora Therap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-atricure-atrc-and-neumora-therapeutics-inc-nmra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-atricure-atrc-and-neumora-therapeutics-inc-nmra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","ATRC","BK4007","BK4137","NMRA","BK4082"],"gpt_icon":0},{"id":"2511872669","title":"Positive Prospects for Neumora Therapeutics: Buy Rating Supported by Leadership Change and Strategic R&D Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2511872669","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511872669?lang=en_us&edition=fundamental","pubTime":"2025-02-14 19:25","pubTimestamp":1739532348,"startTime":"0","endTime":"0","summary":"Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report). The associated pri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-prospects-for-neumora-therapeutics-buy-rating-supported-by-leadership-change-and-strategic-rd-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-prospects-for-neumora-therapeutics-buy-rating-supported-by-leadership-change-and-strategic-rd-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2511505975","title":"Neumora Therapeutics Announces Leadership Changes and Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2511505975","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511505975?lang=en_us&edition=fundamental","pubTime":"2025-02-14 06:17","pubTimestamp":1739485076,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. ( ($NMRA) ) has shared an update. On February 13, 2025, Neumora Therapeutics announced leadership changes effective Febr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-announces-leadership-changes-and-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-announces-leadership-changes-and-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4600","NMRA","BK4023","BK4588","BK4595","BK4585","BK4596","STRK","BK4007","BK4516","LENZ"],"gpt_icon":0},{"id":"2511526900","title":"Neumora Therapeutics Names Paul Berns as CEO, Michael Milligan as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2511526900","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511526900?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:57","pubTimestamp":1739455057,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) said Thursday that Paul Berns, its co-founder and executive chair of the board, has been named to succeed Henry Gosebruch as chief executive officer, effective Friday.The c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","NMRA","BK4139"],"gpt_icon":0},{"id":"2511546707","title":"Neumora Therapeutics Announces Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2511546707","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511546707?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:00","pubTimestamp":1739448003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA1ZS0DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2511467945","title":"Neumora Therapeutics Inc - Paul L. Berns to Serve as CEO and Chairman of Neumora","url":"https://stock-news.laohu8.com/highlight/detail?id=2511467945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511467945?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:00","pubTimestamp":1739448003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA1ZS0DV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2511460535","title":"Neumora Therapeutics Inc - BILL Aurora to Serve as COO and Cdo, Michael Milligan as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2511460535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511460535?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:00","pubTimestamp":1739448003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA1ZS0DV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2511954955","title":"Neumora Therapeutics Announces Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2511954955","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511954955?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:00","pubTimestamp":1739448000,"startTime":"0","endTime":"0","summary":"Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board. Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael Milligan to serve as chief financial officer. “Neumora is poised to reach its potential, working to maximize shareholder value, and most importantly, to make a difference for the millions of people living with brain diseases,” said Paul L. Berns. “We have seven novel neuroscience programs in the pipeline and four clinical data readouts on the horizon, including data from the ongoing Phase 3 program with navacaprant in depression. This provides significant opportunities to improve the treatment of brain diseases and address unmet needs by bringing novel medicines to people who need them most.”“I am honored to serve as president of Neumora,” said Dr. Joshua Pinto. “Neumora is in a strong position, advancing studies in some of the most prevalent brain diseases with multiple near-term ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-therapeutics-announces-leadership-transition-120000381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","NMRA","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":111,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"NMRA","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.42},{"market":"US","date":"2024-11-12","symbol":"NMRA","fiscalQuarterEnding":"2024/09","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.375,"hold":0.625,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.625,"analysts":8,"updateTime":1743566400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NMRA","date":"2025-06-27","current":-0.501055,"percent":0.906921,"low":-19.620035,"twenty":-11.897527,"median":-6.552046,"eighty":-0.939895,"high":-0.385538,"avg":-7.16271,"sd":5.251111,"marketCap":129301288},"quantilePoints":[{"date":"2023-09-15","current":-19.620035,"twenty":-19.620035,"median":-19.620035,"eighty":-19.620035,"marketCap":2583134632},{"date":"2023-09-22","current":-12.753675,"twenty":-18.754446,"median":-15.453663,"eighty":-12.753675,"marketCap":1679123396},{"date":"2023-09-28","current":-13.691957,"twenty":-17.415667,"median":-13.628246,"eighty":-12.772209,"marketCap":1802655635},{"date":"2023-10-05","current":-13.813351,"twenty":-16.65135,"median":-13.723658,"eighty":-12.773914,"marketCap":1818638110},{"date":"2023-10-13","current":-11.180579,"twenty":-14.994038,"median":-13.691957,"eighty":-12.763183,"marketCap":1472012710},{"date":"2023-10-20","current":-11.493728,"twenty":-13.94093,"median":-13.080265,"eighty":-11.639864,"marketCap":1513241282},{"date":"2023-10-27","current":-14.254079,"twenty":-14.080107,"median":-13.080265,"eighty":-11.690896,"marketCap":1876663508},{"date":"2023-11-03","current":-10.734234,"twenty":-13.848145,"median":-12.776843,"eighty":-11.493728,"marketCap":1667466680},{"date":"2023-11-10","current":-10.420012,"twenty":-13.826354,"median":-12.7442,"eighty":-11.403032,"marketCap":1618655149},{"date":"2023-11-17","current":-11.79624,"twenty":-13.813351,"median":-12.154821,"eighty":-11.403032,"marketCap":1832439792},{"date":"2023-11-24","current":-11.717599,"twenty":-13.766958,"median":-11.806071,"eighty":-11.438475,"marketCap":1820223526},{"date":"2023-12-01","current":-12.041995,"twenty":-13.704638,"median":-11.815901,"eighty":-11.48267,"marketCap":1870615621},{"date":"2023-12-08","current":-12.26809,"twenty":-13.59002,"median":-11.825731,"eighty":-11.493283,"marketCap":1905737383},{"date":"2023-12-15","current":-14.381583,"twenty":-13.717318,"median":-11.894542,"eighty":-11.493728,"marketCap":2234049513},{"date":"2023-12-22","current":-13.75245,"twenty":-13.821153,"median":-12.041995,"eighty":-11.521564,"marketCap":2136319390},{"date":"2023-12-29","current":-16.848963,"twenty":-14.008036,"median":-12.137729,"eighty":-11.563317,"marketCap":2617334836},{"date":"2024-01-05","current":-16.111698,"twenty":-14.24211,"median":-12.26809,"eighty":-11.573312,"marketCap":2502807349},{"date":"2024-01-12","current":-14.991056,"twenty":-14.660761,"median":-12.728927,"eighty":-11.585874,"marketCap":2328725569},{"date":"2024-01-19","current":-14.411074,"twenty":-14.428768,"median":-12.751722,"eighty":-11.613398,"marketCap":2238630612},{"date":"2024-01-26","current":-14.843603,"twenty":-15.020547,"median":-12.776843,"eighty":-11.648787,"marketCap":2305820071},{"date":"2024-02-02","current":-14.991056,"twenty":-15.264335,"median":-13.370218,"eighty":-11.652719,"marketCap":2328725569},{"date":"2024-02-09","current":-17.1537,"twenty":-15.346909,"median":-13.691957,"eighty":-11.671529,"marketCap":2664672864},{"date":"2024-02-16","current":-18.490607,"twenty":-15.539581,"median":-13.783396,"eighty":-11.691031,"marketCap":2872349373},{"date":"2024-02-23","current":-18.500437,"twenty":-15.932789,"median":-13.819852,"eighty":-11.69454,"marketCap":2873876407},{"date":"2024-03-01","current":-17.330643,"twenty":-16.668088,"median":-13.939224,"eighty":-11.709735,"marketCap":2692159461},{"date":"2024-03-08","current":-12.297819,"twenty":-16.990518,"median":-13.97363,"eighty":-11.717599,"marketCap":2901363004},{"date":"2024-03-15","current":-10.189453,"twenty":-16.81554,"median":-13.826354,"eighty":-11.69454,"marketCap":2403946708},{"date":"2024-03-22","current":-9.414974,"twenty":-16.668088,"median":-13.783396,"eighty":-11.650753,"marketCap":2221227691},{"date":"2024-03-28","current":-8.492333,"twenty":-16.613039,"median":-13.722203,"eighty":-11.579976,"marketCap":2003553733},{"date":"2024-04-05","current":-9.246609,"twenty":-16.364935,"median":-13.534996,"eighty":-11.491504,"marketCap":2181506166},{"date":"2024-04-12","current":-9.435178,"twenty":-16.111698,"median":-12.865966,"eighty":-11.216259,"marketCap":2225994275},{"date":"2024-04-19","current":-7.105005,"twenty":-15.954415,"median":-12.753675,"eighty":-10.606446,"marketCap":1676248365},{"date":"2024-04-26","current":-6.123304,"twenty":-15.846283,"median":-12.728927,"eighty":-10.162515,"marketCap":1444640411},{"date":"2024-05-03","current":-6.231441,"twenty":-15.669339,"median":-12.297819,"eighty":-9.792112,"marketCap":1470152824},{"date":"2024-05-10","current":-6.135514,"twenty":-15.610358,"median":-12.155389,"eighty":-9.435178,"marketCap":1558549450},{"date":"2024-05-17","current":-6.047595,"twenty":-15.433415,"median":-12.120637,"eighty":-9.273547,"marketCap":1536216091},{"date":"2024-05-24","current":-5.846636,"twenty":-15.423584,"median":-11.91675,"eighty":-8.957021,"marketCap":1485168412},{"date":"2024-05-31","current":-6.085275,"twenty":-15.399992,"median":-11.884712,"eighty":-8.469435,"marketCap":1545787530},{"date":"2024-06-07","current":-6.235993,"twenty":-15.362637,"median":-11.806071,"eighty":-7.09423,"marketCap":1584073290},{"date":"2024-06-14","current":-6.248553,"twenty":-15.342977,"median":-11.75692,"eighty":-6.904314,"marketCap":1587263770},{"date":"2024-06-21","current":-5.557759,"twenty":-15.335113,"median":-11.717599,"eighty":-6.419582,"marketCap":1411787373},{"date":"2024-06-28","current":-5.777557,"twenty":-15.335113,"median":-11.707769,"eighty":-6.279953,"marketCap":1467620772},{"date":"2024-07-05","current":-6.129234,"twenty":-15.228947,"median":-11.690896,"eighty":-6.264891,"marketCap":1556954210},{"date":"2024-07-12","current":-7.253346,"twenty":-15.12278,"median":-11.653703,"eighty":-6.277441,"marketCap":1842502165},{"date":"2024-07-15","current":-6.939348,"twenty":-15.110984,"median":-11.648787,"eighty":-6.278697,"marketCap":1762740166},{"date":"2024-08-02","current":-7.931581,"twenty":-15.099188,"median":-11.648787,"eighty":-6.279953,"marketCap":2014788082},{"date":"2024-08-09","current":-6.56038,"twenty":-15.040207,"median":-11.579976,"eighty":-6.279953,"marketCap":1798711865},{"date":"2024-08-16","current":-6.881395,"twenty":-14.991056,"median":-11.493728,"eighty":-6.279953,"marketCap":1886727125},{"date":"2024-08-23","current":-6.712133,"twenty":-14.991056,"median":-11.447336,"eighty":-6.393648,"marketCap":1840319079},{"date":"2024-08-30","current":-6.54287,"twenty":-14.922244,"median":-11.299816,"eighty":-6.436952,"marketCap":1793911032},{"date":"2024-09-06","current":-6.297731,"twenty":-14.859331,"median":-10.957407,"eighty":-6.374465,"marketCap":1726699379},{"date":"2024-09-13","current":-6.904742,"twenty":-14.68632,"median":-10.606446,"eighty":-6.374465,"marketCap":1893128235},{"date":"2024-09-20","current":-7.430039,"twenty":-14.481851,"median":-10.304733,"eighty":-6.410301,"marketCap":2037153206},{"date":"2024-09-27","current":-7.634321,"twenty":-14.416972,"median":-9.973946,"eighty":-6.432454,"marketCap":2093162917},{"date":"2024-10-04","current":-7.905725,"twenty":-14.387481,"median":-9.835887,"eighty":-6.454177,"marketCap":2167575819},{"date":"2024-10-11","current":-8.988421,"twenty":-14.365855,"median":-9.536197,"eighty":-6.471402,"marketCap":2464427288},{"date":"2024-10-18","current":-9.898936,"twenty":-14.275648,"median":-9.492422,"eighty":-6.494727,"marketCap":2714070572},{"date":"2024-10-25","current":-7.587628,"twenty":-14.23812,"median":-9.435178,"eighty":-6.5109,"marketCap":2080360698},{"date":"2024-10-31","current":-7.126534,"twenty":-14.186945,"median":-9.414974,"eighty":-6.517189,"marketCap":1953938778},{"date":"2024-11-08","current":-7.599301,"twenty":-14.11026,"median":-9.329429,"eighty":-6.519524,"marketCap":2083561252},{"date":"2024-11-15","current":-6.430581,"twenty":-14.036864,"median":-9.246609,"eighty":-6.508113,"marketCap":1888648838},{"date":"2024-11-22","current":-5.330396,"twenty":-14.008036,"median":-9.078889,"eighty":-6.434404,"marketCap":1565526710},{"date":"2024-11-29","current":-5.467919,"twenty":-13.980511,"median":-8.972721,"eighty":-6.336098,"marketCap":1605916976},{"date":"2024-12-06","current":-5.313893,"twenty":-13.902792,"median":-8.614876,"eighty":-6.276185,"marketCap":1560679878},{"date":"2024-12-13","current":-5.819979,"twenty":-13.839429,"median":-8.495238,"eighty":-6.248553,"marketCap":1709316057},{"date":"2024-12-20","current":-5.775971,"twenty":-13.821153,"median":-8.377845,"eighty":-6.222869,"marketCap":1696391172},{"date":"2024-12-27","current":-6.238049,"twenty":-13.812967,"median":-8.200475,"eighty":-6.175381,"marketCap":1832102465},{"date":"2025-01-03","current":-1.083682,"twenty":-13.811432,"median":-8.147945,"eighty":-6.157876,"marketCap":318275296},{"date":"2025-01-10","current":-1.303719,"twenty":-13.766574,"median":-7.931581,"eighty":-6.140538,"marketCap":382899721},{"date":"2025-01-17","current":-1.193701,"twenty":-13.753032,"median":-7.891133,"eighty":-6.119668,"marketCap":350587508},{"date":"2025-01-24","current":-1.1882,"twenty":-13.716154,"median":-7.812392,"eighty":-6.085275,"marketCap":348971898},{"date":"2025-01-31","current":-1.056178,"twenty":-13.615504,"median":-7.634321,"eighty":-6.067691,"marketCap":310197242},{"date":"2025-02-07","current":-1.07268,"twenty":-13.546812,"median":-7.564281,"eighty":-5.978405,"marketCap":315044074},{"date":"2025-02-14","current":-0.929656,"twenty":-13.337262,"median":-7.53602,"eighty":-5.966304,"marketCap":273038198},{"date":"2025-02-21","current":-0.940658,"twenty":-13.1053,"median":-7.470895,"eighty":-5.920328,"marketCap":276269419},{"date":"2025-02-28","current":-0.852643,"twenty":-12.883791,"median":-7.424202,"eighty":-5.847483,"marketCap":250419649},{"date":"2025-03-07","current":-1.009931,"twenty":-12.773914,"median":-7.253346,"eighty":-5.800175,"marketCap":246207962},{"date":"2025-03-14","current":-0.930199,"twenty":-12.763183,"median":-7.144044,"eighty":-5.763741,"marketCap":226770492},{"date":"2025-03-21","current":-0.770737,"twenty":-12.752113,"median":-7.105005,"eighty":-5.687956,"marketCap":187895550},{"date":"2025-03-28","current":-0.730871,"twenty":-12.743752,"median":-7.036301,"eighty":-5.574632,"marketCap":178176815},{"date":"2025-04-04","current":-0.564099,"twenty":-12.730087,"median":-6.998128,"eighty":-5.417311,"marketCap":137520105},{"date":"2025-04-11","current":-0.476129,"twenty":-12.580434,"median":-6.945391,"eighty":-5.374404,"marketCap":116074096},{"date":"2025-04-17","current":-0.41859,"twenty":-12.352677,"median":-6.926527,"eighty":-5.321594,"marketCap":102046721},{"date":"2025-04-25","current":-0.497989,"twenty":-12.291873,"median":-6.904742,"eighty":-1.375231,"marketCap":121403202},{"date":"2025-05-02","current":-0.511809,"twenty":-12.245663,"median":-6.881395,"eighty":-1.223405,"marketCap":124772347},{"date":"2025-05-09","current":-0.423699,"twenty":-12.15573,"median":-6.846375,"eighty":-1.1893,"marketCap":103292222},{"date":"2025-05-16","current":-0.417316,"twenty":-12.148314,"median":-6.834702,"eighty":-1.12879,"marketCap":107691766},{"date":"2025-05-23","current":-0.449909,"twenty":-12.121955,"median":-6.75723,"eighty":-1.07488,"marketCap":116102658},{"date":"2025-05-30","current":-0.450473,"twenty":-12.120637,"median":-6.747152,"eighty":-1.061679,"marketCap":116248231},{"date":"2025-06-06","current":-0.507762,"twenty":-12.041995,"median":-6.685868,"eighty":-1.033834,"marketCap":131031991},{"date":"2025-06-13","current":-0.562731,"twenty":-11.924033,"median":-6.5954,"eighty":-0.989998,"marketCap":145217284},{"date":"2025-06-20","current":-0.488895,"twenty":-11.91238,"median":-6.57789,"eighty":-0.951354,"marketCap":126163379},{"date":"2025-06-27","current":-0.501055,"twenty":-11.897527,"median":-6.552046,"eighty":-0.939895,"marketCap":129301288}],"updateTime":1751146815668}}}